Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma
Open Access
- 31 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 11 (1), 47
- https://doi.org/10.1186/1471-2407-11-47
Abstract
Background: Epithelial cell adhesion molecule (EpCAM) has been used as surrogate marker for the quantification of circulating tumour cells (CTC). Our aim was to prospectively study the value of a real-time RT-PCR assay for EpCAM detection in the peripheral blood and peritoneal cavity of patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). Methods: From 48 patients with PDAC (40 resectable, 8 unresectable) and 10 patients with chronic pancreatitis undergoing pancreatectomy 10 ml of venous blood was drawn preoperatively (PB) and postoperatively (POB, day 1 (D1B), day 7 (D7B) and after 6 weeks (6WB). Of all patients undergoing pancreatectomy, 40 ml peritoneal lavage fluid was taken preoperatively and postoperatively. A real-time RT-PCR assay (TaqMan, ABI Prism 7700) was developed for the detection of EpCAM mRNA. To discriminate between EpCAM-positive and negative samples a cut-off was applied. Median postoperative follow-up was 24.0 months (range: 0.7 - 41.3). Results: PB was EpCAM-positive (+) in 25% of patients versus 65% of patients in POB (p < 0.0001). EpCAM(+) was noted at D1B, D7B and 6WB was found in 28.6%, 23.1% and 23.5% of patients respectively. Preoperative peritoneal lavage fluid was EpCAM(+) in 10.3% versus 53.8% of patients postoperatively (p < 0.0001). At none of the time-points, an association was found between EpCAM positivity in blood and/or peritoneal cavity and cancer-specific or disease-free survival. Also, no significant associations were found between clinicopathological variables and perioperative EpCAM positivity. Conclusions: Despite a significant increase in EpCAM counts in postoperative blood and peritoneal lavage fluid this was not associated with worse prognosis after pancreatectomy for PDAC. Trial registration: Clinicaltrials.gov NCT00495924This publication has 24 references indexed in Scilit:
- Role of cancer stem cells in pancreatic ductal adenocarcinomaNature Reviews Clinical Oncology, 2009
- Circulating and Disseminated Tumor Cells in the Management of Breast CancerAmerican Journal of Clinical Pathology, 2009
- The Emerging Role of EpCAM in Cancer and Stem Cell SignalingCancer Research, 2009
- Patterns of recurrence after curative resection of pancreatic ductal adenocarcinomaEuropean Journal of Surgical Oncology, 2009
- The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal CancerAnnals of Surgery, 2009
- Are circulating tumor cells predictive of overall survival?Nature Reviews Clinical Oncology, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Results of Pancreaticoduodenectomy in Patients With Periampullary AdenocarcinomaAnnals of Surgery, 2008
- Detection, clinical relevance and specific biological properties of disseminating tumour cellsNature Reviews Cancer, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004